Innovotech Inc (IOT) Fair Value & Analysis
Healthcare · CA · Market cap C$5.4M
Fair value as of: Jun 26, 2026
From 14 valuation models · updated 6 days ago
Share price −22.7% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.1000 – C$0.4000 · fair‑value band C$0.0300 – C$0.0400 · the C$0.1000 price screens above the C$0.0400 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Innovotech Inc (IOT) currently trades at C$0.1000, while our model-based Fair Value estimate is C$0.0400 — implying the stock looks roughly 60.0% overvalued today. We read business quality at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Innovotech Inc generated revenue of C$4.0M at a net margin of -9.2%. Revenue declined 44.0% year over year. It earns a return on equity of -12.7%. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices testing; bacteriophage testing; and analytical services. The company serves customers in the sector of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Innovotech Inc reported revenue of C$4.5M in FY2025 versus C$1.5M in FY2021, a compound +32.3%/yr. Reported net income was C$94.4K in FY2025, compounding −28.8%/yr from FY2021.
Is IOT fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Innovotech Inc (IOT) undervalued?
What is the fair value of IOT?
What is the quality score of IOT?
What is the revenue of Innovotech Inc (IOT)?
What is the net profit margin of IOT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.